Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  European Neuropsychopharmacology

• Publication date

  2014-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.euroneuro.2013.12.003PMID 24406025
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disgust in contamination-based obsessive–compulsive disorder: a review and model

  2010cited by this paper
• A double‐blind, placebo‐controlled pilot study of ondansetron for patients with obsessive‐compulsive disorder

  2010influential reference
• Ondansetron Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder

  2009influential reference
• The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

  2009cited by this paper
• The expert consensus guideline series

  2009cited by this paper
• Safety of ondansetron loading doses in children with cancer

  2008cited by this paper
• Practice guideline for the treatment of patients with obsessive-compulsive disorder.

  2007cited by this paper
• A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

  2006influential reference
• A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

  2006cited by this paper
• Quality of life of relatives of patients with obsessive-compulsive disorder.

  2006cited by this paper
• Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders.

  2006cited by this paper
• Impact of obsessive-compulsive disorder on quality of life.

  2006cited by this paper
• 5‐Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors

  2005cited by this paper
• Quality-of-life impairment in depressive and anxiety disorders.

  2005cited by this paper
• Effect of 5-HT3 receptor antagonists on the discriminative stimulus properties of morphine in rats

  2005cited by this paper
• μ opioid receptor gene as a candidate for the study of obsessive compulsive disorder with and without tics

  2004cited by this paper
• Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder.

  2003influential reference
• 114 CURRENT AND EXPERIMENTAL THERAPEUTICS OF OCD

  2002cited by this paper
• The Central 5-HT3 Receptor in CNS Disorders

  1998cited by this paper
• Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.

  1998cited by this paper
• Structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version : scoresheet

  1997cited by this paper
• Structured clinical interview for DSM-IV axis I disorders : SCID-I: clinical version : administration booklet

  1997cited by this paper
• m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.

  1995cited by this paper
• The Yale-Brown Obsessive-Compulsive Scale: measures of internal consistency.

  1994cited by this paper
• Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation.

  1993cited by this paper
• Neural Mechanisms of Drug Reinforcement a

  1992cited by this paper
• Closing remarks. Ondansetron: effects on gastrointestinal motility.

  1991cited by this paper
• Persisting pain after cholecystectomy. A prospective investigation.

  1991cited by this paper
• The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

  1989cited by this paper
• The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability

  1989cited by this paper
• Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.

  1988cited by this paper

• Randomized Controlled Trial of the Effects of High-Dose Ondansetron on Clinical Symptoms and Brain Connectivity in Obsessive-Compulsive and Tic Disorders.

  2025cites this paper
• Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive–compulsive disorder: a systematic review and meta-analysis of randomized clinical trials

  2023cites this paper
• Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial

  2022cites this paper
• Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomised controlled trials

  2022cites this paper
• Obsessive-Compulsive Disorder Treatment Based on Neurocircuits

  2022cites this paper
• Correlations between single nucleotide polymorphisms in obsessive-compulsive disorder with the clinical features or response to therapy.

  2022cites this paper
• Granisetron Augmentation of Sertraline in Obsessive-Compulsive Disorder: A Double-Blind Placebo-Controlled, Randomized Clinical Trial

  2022cites this paper
• Toward a neurocircuit-based taxonomy to guide treatment of obsessive–compulsive disorder

  2021cites this paper
• Obsessive Compulsive Disorder: Neurobiology and Treatment

  2021cites this paper
• Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

  2021cites this paper
• Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder.

  2021cites this paper
• Ondansetron Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder: A Randomized Placebo-Controlled Clinical Trial

  2020influential citation
• Beneficial effects of physical activity on depressive and OCD-like behaviors in the male offspring of morphine-abstinent rats.

  2020cites this paper
• Pharmacological Treatments for Obsessive-Compulsive and Related Disorders: A Transdiagnostic Perspective

  2019cites this paper
• Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)

  2019cites this paper
• Lamotrigine Uses in Psychiatric Practice.

  2019cites this paper
• PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics

  2019cites this paper
• Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study.

  2019influential citation
• Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial

  2019cites this paper
• Theoretical models of Obsessive-Compulsive Disorder (OCD): a perspective on future approaches

  2019cites this paper
• High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions

  2018cites this paper
• The Safety and Efficacy of Ondansetron in the Treatment of Obsessive Compulsive Disorder

  2017cites this paper
• Is Ondansetron Augmentation Effective in Obsessive-Compulsive Disorder?

  2017cites this paper
• Pharmacological Augmentations of SRIs for Obsessive Compulsive Disorder

  2017cites this paper
• Lamotrigine Uses in Psychiatric Practice-Beyond Bipolar Prophylaxis a Hope or Hype?

  2017cites this paper
• Biological Models and Treatments for Obsessive‐Compulsive Related Disorders for Adults

  2017cites this paper
• Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research.

  2017cites this paper
• Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study

  2016cites this paper
• Common variants of HTR3 genes are associated with obsessive-compulsive disorder and its phenotypic expression

  2016cites this paper
• Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder.

  2015cites this paper
• Obsessive-compulsive disorder: Overview and standard treatment strategies

  2015cites this paper
• Treating OCD: what to do when first-line therapies fail

  2015cites this paper
• Are 5‐HT3 antagonists effective in obsessive–compulsive disorder? A systematic review of literature

  2015influential citation
• Biological treatments for obsessive-compulsive and related disorders

  2015cites this paper
• Obsessive-Compulsive Disorder: Diagnosis, Epidemiology, Etiology, and Treatment

  2015cites this paper
• 5-HT2A/C receptors do not mediate the attenuation of compulsive checking by mCPP in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).

  2015cites this paper
• Pharmacological treatment of obsessive-compulsive disorder.

  2014cites this paper
• Management of Obsessive-Compulsive Disorder

  2014cites this paper
• An updated review of antidepressants with marked serotonergic effects in obsessive–compulsive disorder

  2014cites this paper
• Emerging drugs to treat obsessive–compulsive disorder

  2014cites this paper
• Pharmacologic treatment of obsessive-compulsive disorder comorbidity

  2014cites this paper